Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|20 CitationsGLP-1 & MetabolicFemale-friendly

MOTS-c Dosing Protocol: Metabolic Research Guide

Also known as: Mitochondrial Exercise-Mimetic Peptide, 12S rRNA-c Peptide

Dose Range
5–10 mgResearch range
0Typical research window: 5–10 mg15 mg

Studied in mitochondrial bioenergetics research (Lee et al., Cell Metabolism; Reynolds et al., Nature Comms). Typical protocols run 5 mg 2–3× weekly.

Protocol at a Glance
How Often
2–3× weekly

5 mg 2–3× per week (or 10 mg once weekly) SubQ AM pre-exercise

A Typical Run
4–8 weeks

4–8 week mitochondrial block followed by 4 weeks off.

How It's Taken
Vial

SubQ injection (AM prior to training)

Evidence
Emerging

Cell Metabolism mitochondrial & exercise-mimetic studies

Half-Life & 72-Hour Clearance Shape
Not established in humans

Not established in humans; no published human pharmacokinetic data

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

10 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 5 mg in every mL (50 mcg per unit)
0u10u20u30u40u50u
Low end: 5 mg100 units
High end: 10 mg200 units

All U-100: 100 units = 1 mL. 2 doses in the vial at the low end (1 doses at the high end).

Track the doses you run

Save MOTS-c to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

MOTS-c supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$135.00
50mg vial
$2.70/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$109.99
40mg vial
$2.75/mg
Bulletproof BioLabs
ILS Laboratories HPLC COA COA-2026-8RKIU-, lot BPB-2610-001
US Domestic Vial
Vendor-supplied list price (Nov 7, 2026; store requires login)
$120.00
40mg vial
$3.00/mg
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$31.00 net$62.00
10mg Lyophilized Vial
$3.10/mg$6.20/mg retail
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$43.00
10mg vial
$4.30/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$49.00
10mg vial
$4.90/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-6246893 (99.45%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$51.00
10mg vial
$5.10/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$55.00
10mg vial
$5.50/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$99.00
10mg vial
$9.90/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$200.00
20mg vial
$10.00/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$109.97
10mg vial
$11.00/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$116.00
10mg vial
$11.60/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Mitochondrial-Derived Cytoprotective & Bioenergetic Peptide (MDP)
Administration Route
Under-the-skin injection (Intraperitoneal)
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S4.4 (Metabolic Modulators: AMPK / PPARδ / Rev-ErbA Agonists)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking

Bottom Line Up Front

MOTS-c is a mitochondrial-derived peptide that improves insulin sensitivity and metabolic function. It is encoded by mitochondrial DNA. Discovered in 2015. Promising animal data for obesity and diabetes.

Best evidence for

Insulin sensitivity, metabolic health (animal data)

Weakest evidence for

Human weight loss, longevity

Pharma equivalent

None

Studies on file

20 (14 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. MOTS-c is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA. Research has investigated its role in metabolic regulation, insulin sensitivity, and exercise adaptation.

Mechanisms of Action

  • Activates AMPK pathway
  • Improves insulin sensitivity
  • Enhances fatty acid oxidation
  • Regulates mitochondrial function

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Metabolic Study
animal study
0.5 mg/kgDaily14 daysIntraperitonealanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (MOTS-c)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

14 Human6 Animal

Our findings establish MOTS-c as a dual-function molecule-acting via ROS-CK2A-MYH9 signaling to activate nuclear antioxidant defenses and serving as a prognostic biomarker for CPB-related complications. This study bridges mitochondrial dynamics, nuclear transcriptional regulation, and clinical outcomes, offering novel preventive avenues for IRI-associated pathologies.

Limitations: No placebo control reported.

2025|Redox biology
PubMed

In addition, the key role of MOTS-c in the major diabetes-related complications is specifically explored, with a special focus on its protective and therapeutic potential in diabetic cardiomyopathy. Beyond summarising its multifaceted roles, this review also uniquely compiles and discusses the distinct exogenous MOTS-c therapeutic approaches, including varying doses and dosing schedules, applied in preclinical metabolic disease studies, thereby providing valuable insights into future translational research.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Life sciences
PubMed

A Mighty Mitochondrial Microprotein: The Protective Role of MOTS-c in Acute Lung Injury. (American journal of respiratory cell and molecular biology, 2025)

Limitations: Animal study only — human translation uncertain.

2025|American journal of respiratory cell and molecular biology
PubMed

MOTS-c negatively correlates with HBV DNA expression (R=-0.71), and its AUC (the area under the curve) for distinguishing CHB from healthy controls is 0.9530, and IA (immune reactive) from IC (inactive HBV carrier) is 0.8689. Inhibition of HBV replication (with a 50-70%&#x2009;inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.

Limitations: No placebo control reported.

2024|Gut
PubMed

More importantly, MOTS-c displays a marked anti-tumor effect on OC growth without systemic toxicity in vivo. In conclusion, this study reveals a crucial role of MOTS-c in OC and provides a possibility for MOTS-c as a therapeutic target for the treatment of this manlignacy.

Limitations: No placebo control reported.

2024|Advanced science (Weinheim, Baden-Wurttemberg, Germany)
PubMed

Notably, Nrf2 deficiency abolished the protective function of MOTS-c in mice with RP. In conclusion, MOTS-c alleviates RP by protecting mitochondrial function through an Nrf2-dependent mechanism, indicating that MOTS-c may be a novel potential protective agent against RP.

Limitations: Animal study only — human translation uncertain.

2024|Antioxidants (Basel, Switzerland)
PubMed

By using a Bcl-2 inhibitor or adeno-associated virus (AAV)-mediated Bcl-2 knockdown, we further confirm that MOTS-c improves NASH-induced mitochondrial dysfunction, inflammation, and fibrosis, which are dependent on Bcl-2 function. Therefore, our findings show that MOTS-c is a potential therapeutic agent to inhibit the progression of NASH.

Limitations: No placebo control reported.

2024|Cell reports
PubMed

However, treatment with the AMPK pathway inhibitor compound C (CC) abolishes the positive effect of MOTS-c on LPS stress. Collectively, our research suggests that MOTS-c may attenuate myocardial injury in septic cardiomyopathy by activating AMPK and provides a new idea for therapeutic strategies in septic cardiomyopathy.

Limitations: No placebo control reported.

2023|Acta biochimica et biophysica Sinica
PubMed

Therefore, this article reviewed the distribution and function of MOTS-c in the tissue, discussed the latest research developments in the regulation of osteoblasts and osteoclasts, and proposed potential molecular mechanisms for the effect of exercise on the regulation of bone metabolism. This review provides a theoretical reference for establishing methods to prevent and treat skeletal metabolic diseases.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2023|Frontiers in physiology
PubMed

This article aims to summarize and interpret the interesting and updated findings of MOTS-c-associated genes and pathways involved in pathological metabolic processes. Finally, it is expected to develop novel diagnostic markers and treatment approaches with MOTS-c to prevent and treat metabolic disorders in the future.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2023|Metabolites
PubMed

This review focuses mainly on recent advances in MOTS-c research with regards to diabetes, including both type 1 and type 2. The emerging understanding of MOTS-c in diabetes may provide insight into the development of new therapies for diabetes and other age or senescence-related diseases.

Limitations: No placebo control reported. Review article — no new primary data.

2023|Diabetes &amp; metabolism journal
PubMed

Throughout this paper, we discussed the discovery and physiological function of mitochondrial-derived polypeptide MOTS-c, and the application of MOTS-c in the treatment of various diseases, such as aging, cardiovascular disease, insulin resistance, and inflammation. To provide additional ideas for future research and development, we tapped into the molecular mechanisms and therapeutic potentials of MOTS-c to improve diseases and combined the technology with synthetic biology in order to offer a new approach to its development and application.

Limitations: No placebo control reported. Review article — no new primary data.

2023|Frontiers in endocrinology
PubMed

Additionally, HR promoted ferroptosis in MLE-12&#xa0;cells, and MOTS-c inhibited ferroptosis against HR through the PPAR&#x3b3; signaling pathway. These findings highlight the therapeutic potential of MOTS-c for improving postoperative ALI induced by cardiac surgery.

Limitations: No placebo control reported.

2023|European journal of pharmacology
PubMed

In addition, we found that MOTS-c protects pancreatic &#x3b2;-cell from STZ-mediated injury. Taken together, our findings demonstrate that MOTS-c could be a promising strategy for the treatment of GDM.

Limitations: Animal study only — human translation uncertain.

2022|Pharmacological research
PubMed

Exogenous MOTS-c also stimulates thermogenesis in subcutaneous white adipose tissues, thereby enhancing energy expenditure and contributing to the anti-obesity effects of exercise training. This review briefly summarizes the mitohormetic mechanisms of exercise with an emphasis on MOTS-c.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2022|Diabetes &amp; metabolism journal
PubMed

Aging is characterized by gradual loss of (mitochondrial) metabolic balance, decreased muscle homeostasis and eventual diminished physical capability, which potentially can be reversed with MOTS-c treatment. This review examines the latest findings on biological effects of MOTS-c as a nuclear regulatory peptide and focuses on the role of MOTS-c in aging and age-related disorders, including mechanisms of action and therapeutic potential.

Limitations: No placebo control reported. Review article — no new primary data.

2022|International journal of molecular sciences
PubMed

These results suggest that through inhibition of myostatin, MOTS-c could be a potential therapy for insulin resistance-induced skeletal muscle atrophy as well as other muscle wasting phenotypes including sarcopenia.NEW & NOTEWORTHY MOTS-c, a mitochondrial-derived peptide reduces high-fat-diet-induced muscle atrophy signaling by reducing myostatin expression. The CK2-PTEN-mTORC2-AKT-FOXO1 pathways play key roles in MOTS-c action on myostatin expression.

Limitations: No placebo control reported.

2021|American journal of physiology. Endocrinology and metabolism
PubMed

It is hypothesized that cellular fitness requires the coevolved mitonuclear genomes to coordinate adaptive responses using gene-encoded factors that cross-regulate the opposite genome. This suggests that cellular gene expression requires the bipartite split genomes to operate as a unified system, rather than the nucleus being the sole master regulator.

Limitations: No placebo control reported. Review article — no new primary data.

2020|BioEssays : news and reviews in molecular, cellular and developmental biology
PubMed

In the nucleus, MOTS-c regulated a broad range of genes in response to glucose restriction, including those with antioxidant response elements (ARE), and interacted with ARE-regulating stress-responsive transcription factors, such as nuclear factor erythroid 2-related factor 2 (NFE2L2/NRF2). Our findings indicate that the mitochondrial and nuclear genomes co-evolved to independently encode for factors to cross-regulate each other, suggesting that mitonuclear communication is genetically integrated.

Limitations: No placebo control reported.

2019|Cell metabolism
PubMed

MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. These results suggest that mitochondria may actively regulate metabolic homeostasis at the cellular and organismal level via peptides encoded within their genome.

Limitations: No placebo control reported.

2015|Cell metabolism
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Limited human research
  • •Exercise mimetic effects under investigation
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get MOTS-c, baseline labs & clinician oversight.

Full MOTS-c $/mg comparison →
50% OFF AUTO-APPLIED$3.10/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy MOTS-c: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Elite Research USA — $2.70/mg (50mg vial, $135.00)
  2. 2. Swift Peptides — $2.75/mg (40mg vial, $109.99)
  3. 3. Bulletproof BioLabs — $3.00/mg (40mg vial, $120.00)

Where is the cheapest place to buy MOTS-c?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Elite Research USA at $2.70/mg (50mg vial, $135.00). We compared 12 US suppliers with live, checked prices.

How much does MOTS-c cost per mg?

Verified US domestic prices currently range from $2.70/mg to $11.60/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is MOTS-c approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.